Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER2 Status in Low-grade Serous Ovarian Tumors.
Němejcová K, Šafanda A, Kendall Bártů M, Hájková N, Drozenová J, Fabian P, Laco J, Matěj R, Méhes G, Škapa P, Stružinská I, Dundr P. Němejcová K, et al. Among authors: skapa p. Int J Gynecol Pathol. 2024 Jul 30. doi: 10.1097/PGP.0000000000001059. Online ahead of print. Int J Gynecol Pathol. 2024. PMID: 39230502
Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer.
Lanickova T, Hensler M, Kasikova L, Vosahlikova S, Angelidou A, Pasulka J, Griebler H, Drozenova J, Mojzisova K, Vankerckhoven A, Laco J, Ryška A, Dundr P, Kocian R, Cibula D, Brtnicky T, Skapa P, Jacob F, Kovar M, Praznovec I, McNeish IA, Halaska MJ, Rob L, Coosemans A, Orsulic S, Galluzzi L, Spisek R, Fucikova J. Lanickova T, et al. Among authors: skapa p. Clin Cancer Res. 2024 Aug 20. doi: 10.1158/1078-0432.CCR-24-1594. Online ahead of print. Clin Cancer Res. 2024. PMID: 39163092
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S, Laco J, Ryska A, Dundr P, Kocian R, Brtnicky T, Skapa P, Capkova L, Kovar M, Prochazka J, Praznovec I, Koblizek V, Taskova A, Tanaka H, Lischke R, Mendez FC, Vachtenheim J Jr, Heinzelmann-Schwarz V, Jacob F, McNeish IA, Halaska MJ, Rob L, Cibula D, Orsulic S, Galluzzi L, Spisek R, Fucikova J. Kasikova L, et al. Among authors: skapa p. Nat Commun. 2024 Mar 21;15(1):2528. doi: 10.1038/s41467-024-46873-w. Nat Commun. 2024. PMID: 38514660 Free PMC article.
Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I, Hájková N, Hojný J, Krkavcová E, Michálková R, Bui QH, Matěj R, Laco J, Drozenová J, Fabian P, Škapa P, Špůrková Z, Cibula D, Frühauf F, Jirásek T, Zima T, Méhes G, Kendall Bártů M, Němejcová K, Dundr P. Stružinská I, et al. Among authors: skapa p. J Mol Diagn. 2024 Apr;26(4):257-266. doi: 10.1016/j.jmoldx.2023.12.004. Epub 2024 Jan 26. J Mol Diagn. 2024. PMID: 38280423
HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma.
Kendall Bártů M, Němejcová K, Michálková R, Stružinská I, Hájková N, Hojný J, Krkavcová E, Laco J, Matěj R, Drozenová J, Méhes G, Fabian P, Hausnerová J, Švajdler M, Škapa P, Cibula D, Zima T, Dundr P. Kendall Bártů M, et al. Among authors: skapa p. Virchows Arch. 2023 Oct;483(4):497-507. doi: 10.1007/s00428-023-03640-4. Epub 2023 Sep 7. Virchows Arch. 2023. PMID: 37676270
Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors.
Šafanda A, Kendall Bártů M, Michálková R, Stružinská I, Drozenová J, Fabián P, Hausnerová J, Laco J, Matěj R, Škapa P, Švajdler M, Špůrková Z, Méhes G, Dundr P, Němejcová K. Šafanda A, et al. Among authors: skapa p. Virchows Arch. 2023 Oct;483(4):509-516. doi: 10.1007/s00428-023-03629-z. Epub 2023 Aug 23. Virchows Arch. 2023. PMID: 37610627
Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases.
Kendall Bártů M, Němejcová K, Michálková R, Bui QH, Drozenová J, Fabian P, Fadare O, Hausnerová J, Laco J, Matěj R, Méhes G, Šafanda A, Singh N, Škapa P, Špůrková Z, Stolnicu S, Švajdler M, Lax SF, McCluggage WG, Dundr P. Kendall Bártů M, et al. Among authors: skapa p. Int J Gynecol Pathol. 2024 Mar 1;43(2):123-133. doi: 10.1097/PGP.0000000000000962. Epub 2023 Jun 14. Int J Gynecol Pathol. 2024. PMID: 37406366
A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.
Stružinská I, Hájková N, Hojný J, Krkavcová E, Michálková R, Dvořák J, Němejcová K, Matěj R, Laco J, Drozenová J, Fabian P, Hausnerová J, Méhes G, Škapa P, Švajdler M, Cibula D, Frühauf F, Bártů MK, Dundr P. Stružinská I, et al. Among authors: skapa p. Diagn Pathol. 2023 Jun 12;18(1):72. doi: 10.1186/s13000-023-01358-0. Diagn Pathol. 2023. PMID: 37303048 Free PMC article.
A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
Němejcová K, Bártů MK, Michálková R, Drozenová J, Fabian P, Fadare O, Hausnerová J, Laco J, Matěj R, Méhes G, Singh N, Stolnicu S, Škapa P, Švajdler M, Stružinská I, Cibula D, Kocian R, Lax SF, McCluggage WG, Dundr P. Němejcová K, et al. Among authors: skapa p. Diagn Pathol. 2023 Feb 6;18(1):15. doi: 10.1186/s13000-023-01300-4. Diagn Pathol. 2023. PMID: 36740684 Free PMC article.
62 results